CoChat
Sign Up
Cited by 17MicroRNA in disease regulationNeurogenesis and neuroplasticity mechanismsNeurotransmitter Receptor Influence on Behavior

Fluoxetine Increases the Expression of miR-572 and miR-663a in Human Neuroblastoma Cell Lines

Open access
Mundalil Vasu, Mahesh, Anitha, Ayyappan, Takahashi, Taro, Thanseem, Ismail, Iwata, Keiko, Asakawa, Tetsuya, Suzuki, Katsuaki·2016·PLOS ONE
DOI 10.1371/journal.pone.0164425PMC PMC5055328
Open this paper in CoChat — free accountOpen PDF

Abstract

Evidence suggests neuroprotective effects of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), on the developed neurons in the adult brain. In contrast, the drug may be deleterious to immature or undifferentiated neural cells, although the mechanism is unclear. Recent investigations have suggested that microRNAs (miRNA) may be critical for effectiveness of psychotropic drugs including SSRI. We investigated whether fluoxetine could modulate expressions of neurologically relevant miRNAs in two neuroblastoma SK-N-SH and SH-SY5Y cell lines. Initial screening results revealed that three (miR-489, miR-572 and miR-663a) and four (miR-320a, miR-489, miR-572 and miR-663a) miRNAs were up-regulated in SK-N-SH cells and SH-SY5Y cells, respectively, after 24 hours treatment of fluoxetine (1-25 μM). Cell viability was reduced according to the dose of fluoxetine. The upregulation of miR-572 and miR-663a was consistent in both the SH-SY5Y and SK-N-SH cells, confirmed by a larger scale culture condition. Our data is the first in vitro evidence that fluoxetine could increase the expression of miRNAs in undifferentiated neural cells, and that putative target genes of those miRNAs have been shown to be involved in fundamental neurodevelopmental processes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0164425

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In vitro, fluoxetine upregulated miR-320a, miR-663a, miR-572, and miR-489 in both SK-N-SH and SHSY5Y cell lines.

    “In vitro, fluoxetine upregulated miR-320a, miR-663a, miR-572, and miR-489 in both SK-N-SH and SHSY5Y cell lines.332”

    From Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential (2023) · cites this paper as [332]

    The Results (Preliminary microRNA screening) report upregulation of miR-489, miR-572, and miR-663a in SK-N-SH cells, and all four listed miRNAs in SH-SY5Y cells. They do not report miR-320a upregulation in SK-N-SH cells, so the claim that all four were upregulated in both lines is not supported. (LLM, conf=0.94)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 46

  1. [1]Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008; 455(7215): 894– 902. 10.1038/nature07455 18923511 PMC2721780 · DOI · Paper page
  2. [2]Sun BK, Kim JH, Choi JS, Hwang SJ, Sung JH. Fluoxetine Decreases the Proliferation and Adipogenic Differentiation of Human Adipose-Derived Stem Cells. Int J Mol Sci. 2015; 16(7): 16655– 68. 10.3390/ijms160716655 26204837 PMC4519971 · DOI
  3. [3]Mun AR, Lee SJ, Kim GB, Kang HS, Kim JS, Kim SJ. Fluoxetine-induced apoptosis in hepatocellular carcinoma cells. Anticancer Res. 2013; 33(9): 3691– 7. 24023297
  4. [4]Stepulak A, Rzeski W, Sifringer M, Brocke K, Gratopp A, Kupisz K, et al Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Ther. 2008; 7(10): 1685– 93. 10.4161/cbt.7.10.6664 18836303 · DOI
  5. [5]Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol. 1994; 23(2): 194– 205. 10.1006/faat.1994.1098 7982528 · DOI
  6. [6]Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RC, et al Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology. 2006; 31(1): 47– 57. 10.1038/sj.npp.1300823 16012532 PMC3118509 · DOI
  7. [7]Man KK, Tong HH, Wong LY, Chan EW, Simonoff E, Wong IC. Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: a systematic review and meta-analysis of observational studies. Neurosci Biobehav Rev. 2015; 49: 82– 9. 10.1016/j.neubiorev.2014.11.020 25498856 · DOI · Paper page
  8. [9]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Arlington, VA, USA American Psychiatric Association, 2013.
  9. [10]Ambros V. The functions of animal microRNAs. Nature 2004; 431(7006): 350– 5. 10.1038/nature02871 15372042 · DOI · Paper page
  10. [11]Huntzinger E and Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011; 12(2): 99– 110. 10.1038/nrg2936 21245828 · DOI · Paper page
  11. [12]Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell. 2013; 153(3): 516– 9. 10.1016/j.cell.2013.04.003 23622238 · DOI
  12. [13]Xu B, Karayiorgou M, Gogos JA. MicroRNAs in psychiatric and neurodevelopmental disorders. Brain Res. 2010; 1338: 78– 88. 10.1016/j.brainres.2010.03.109 20388499 PMC2883644 · DOI
  13. [14]Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2): 215– 33. 10.1016/j.cell.2009.01.002 19167326 PMC3794896 · DOI · Paper page
  14. [15]Forero DA, van der Ven K, Callaerts P, Del-Favero J. miRNA genes and the brain: implications for psychiatric disorders. Hum Mutat. 2010; 31(11): 1195– 204. 10.1002/humu.21344 20725930 · DOI
  15. [16]McNeill E, Van Vactor D. MicroRNAs shape the neuronal landscape. Neuron. 2012; 75(3): 363– 79. 10.1016/j.neuron.2012.07.005 22884321 PMC3441179 · DOI · Paper page
  16. [17]Mellios N, Sugihara H, Castro J, Banerjee A, Le C, Kumar A, et al miR-132, an experience-dependent microRNA, is essential for visual cortex plasticity. Nat Neurosci. 2011; 14(10): 1240– 2. 10.1038/nn.2909 21892155 PMC3183341 · DOI · Paper page
  17. [18]O'Connor RM, Dinan TG, Cryan JF. Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression. Mol Psychiatry. 2012; 17(4): 359– 76. 10.1038/mp.2011.162 22182940 · DOI
  18. [19]Siegel G, Saba R, Schratt G. microRNAs in neurons: manifold regulatory roles at the synapse. Curr Opin Genet Dev. 2011; 21(4): 491– 7. 10.1016/j.gde.2011.04.008 21561760 · DOI
  19. [20]Abu-Elneel K, Liu T, Gazzaniga FS, Nishimura Y, Wall DP, Geschwind DH, et al Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 2008; 9(3): 153– 61. 10.1007/s10048-008-0133-5 18563458 · DOI · Paper page
  20. [21]Talebizadeh Z, Butler MG, Theodoro MF. Feasibility and relevance of examining lymphoblastoid cell lines to study role of microRNAs in autism. Autism Res 2008; 1(4): 240– 50. 10.1002/aur.33 19360674 PMC2768334 · DOI · Paper page
  21. [22]Sarachana T, Zhou R, Chen G, Manji HK, Hu VW. Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med 2010; 2(4): 23 10.1186/gm144 20374639 PMC2873801 · DOI
  22. [23]Ghahramani Seno MM, Hu P, Gwadry FG, Pinto D, Marshall CR, Casallo G, et al Gene and miRNA expression profiles in autism spectrum disorders. Brain Res 2011; 1380: 85– 97. 10.1016/j.brainres.2010.09.046 20868653 · DOI
  23. [24]Mundalil Vasu M, Anitha A, Thanseem I, Suzuki K, Yamada K, Takahashi T, et al Serum microRNA profiles in children with autism. Mol Autism. 2014; 5: 40 10.1186/2040-2392-5-40 25126405 PMC4132421 · DOI
  24. [25]Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 2001 5; Appendix 3: Appendix 3B 10.1002/0471142735.ima03bs21 18432654 · DOI
  25. [26]Riksen EA, Stunes AK, Kalvik A, Gustafsson BI, Snead ML, Syversen U, et al Serotonin and fluoxetine receptors are expressed in enamel organs and LS8 cells and modulate gene expression in LS8 cells. Eur J Oral Sci. 2010; 118(6): 566– 73. 10.1111/j.1600-0722.2010.00778.x 21083617 PMC6422030 · DOI
  26. [27]Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol. 1999; 48(4): 521– 7. 10.1046/j.1365-2125.1999.00040.x 10583022 PMC2014386 · DOI
  27. [28]Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs. 2001; 61(1): 81– 110. 10.2165/00003495-200161010-00010 11217873 · DOI
  28. [29]Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, et al Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci. 1993; 5(3): 322– 9. 10.1176/jnp.5.3.322 8369643 · DOI
  29. [30]Bolo NR, Hodé Y, Nédélec JF, Lainé E, Wagner G, Macher JP. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology. 2000; 23(4): 428– 38. 10.1016/S0893-133X(00)00116-0 10989270 · DOI
  30. [31]Stoll AL, Pope HG Jr, McElroy SL. High-dose fluoxetine: safety and efficacy in 27 cases. J Clin Psychopharmacol 1991 6; 11(3): 225– 6. 10.1097/00004714-199106000-00025 2066466 · DOI
  31. [33]Mancuso R, Hernis A, Agostini S, Rovaris M, Caputo D, Clerici M. MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression. J Transl Med. 2015; 13: 148 10.1186/s12967-015-0504-2 25947625 PMC4429409 · DOI
  32. [34]Yu X, Liu S, Li J, Fan X, Chen Y, Bi X, et al MicroRNA-572 improves early post-operative cognitive dysfunction by down-regulating neural cell adhesion molecule 1. PLoS One. 2015; 10(2): e0118511 10.1371/journal.pone.0118511 25680004 PMC4334516 · DOI
  33. [35]Li S, Leshchyns'ka I, Chernyshova Y, Schachner M, Sytnyk V. The neural cell adhesion molecule (NCAM) associates with and signals through p21-activated kinase 1 (Pak1). J Neurosci. 2013; 33(2): 790– 803. 10.1523/JNEUROSCI.1238-12.2013 23303955 PMC6704904 · DOI
  34. [36]Dallérac G, Zerwas M, Novikova T, Callu D, Leblanc-Veyrac P, Bock E, et al The neural cell adhesion molecule-derived peptide FGL facilitates long-term plasticity in the dentate gyrus in vivo. Learn Mem. 2011; 18(5): 306– 13. 10.1101/lm.2154311 21508096 · DOI
  35. [37]Choi MR, Oh DH, Kim SH, Jung KH, Das ND, Chai YG. Fluoxetine increases the expression of NCAM140 and pCREB in rat C6 glioma cells. Psychiatry Investig. 2012; 9(2): 180– 6. 10.4306/pi.2012.9.2.180 22707970 PMC3372567 · DOI
  36. [38]Shi Y, Chen C, Zhang X, Liu Q, Xu JL, Zhang HR, et al Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. Clin Cancer Res. 2014; 20(7): 1803– 13. 10.1158/1078-0432.CCR-13-2284 24523440 · DOI
  37. [39]Shu R, Wong W, Ma QH, Yang ZZ, Zhu H, Liu FJ, et al APP intracellular domain acts as a transcriptional regulator of miR-663 suppressing neuronal differentiation. Cell Death Dis. 2015; 6: e1651 10.1038/cddis.2015.10 25695604 PMC4669786 · DOI
  38. [40]Fan H, Niu W, He M, Kong L, Zhong A, Zhang Q, et al [ Bioinformatics analysis of differently expressed microRNAs in anxiety disorder] [Article in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2015; 32(5): 641– 6. 10.3760/cma.j.issn.1003-9406.2015.05.007 26418982 · DOI
  39. [41]Kloosterman WP, Steiner FA, Berezikov E, de Bruijn E, van de Belt J, Verheul M, et al Cloning and expression of new microRNAs from zebrafish. Nucleic Acids Res. 2006; 34(9): 2558– 69. 10.1093/nar/gkl278 16698962 PMC3303176 · DOI
  40. [42]Olsen L, Klausen M, Helboe L, Nielsen FC, Werge T. MicroRNAs show mutually exclusive expression patterns in the brain of adult male rats. PLoS One. 2009; 4(10): e7225 10.1371/journal.pone.0007225 19806225 PMC2752988 · DOI
  41. [43]Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ: Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 2010; 15(12): 1176– 89. 10.1038/mp.2009.84 19721432 PMC2990188 · DOI
  42. [45]Barak B, Shvarts-Serebro I, Modai S, Gilam A, Okun E, Michaelson DM, et al Opposing actions of environmental enrichment and Alzheimer's disease on the expression of hippocampal microRNAs in mouse models. Transl Psychiatry. 2013; 3: e304 10.1038/tp.2013.77 24022509 PMC3784766 · DOI
  43. [46]De Santis G, Ferracin M, Biondani A, Caniatti L, Rosaria Tola M, Castellazzi M, et al Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol. 2010; 226(1–2): 165– 71. 10.1016/j.jneuroim.2010.06.009 20637509 · DOI
  44. [47]Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997; 283(3): 1305– 22. 9400006
  45. [48]Herr AS, Tsolakidou AF, Yassouridis A, Holsboer F, Rein T. Antidepressants differentially influence the transcriptional activity of the glucocorticoid receptor in vitro. Neuroendocrinology. 2003; 78(1): 12– 22. 10.1159/000071701 12869795 · DOI
  46. [49]Pariante CM, Kim RB, Makoff A, Kerwin RW. Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol. 2003; 139(6): 1111– 8. 10.1038/sj.bjp.0705357 12871829 PMC1573949 · DOI · Paper page

Cited by

Sorted by citations

Authors
Mundalil Vasu, M., Anitha, A., Takahashi, T., Thanseem, I., Iwata, K., Asakawa, T., & Suzuki, K.
Affiliations
  • Hamamatsu University School of Medicine (JP)
  • University of Fukui (JP)
Corresponding author
Suzuki, Katsuaki
ORCID
Venue
PLOS ONE
Publisher
Public Library of Science (PLoS)
Published
2016-10-07
Volume
11
Issue
10
Pages
e0164425
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0164425
PMC
PMC5055328
OpenAlex
W2529259238
Cited by
17
References
3
Citations by year
2025: 1 · 2024: 1 · 2023: 3 · 2021: 1 · 2020: 4 · 2019: 4 · 2018: 2 · 2017: 1
FWCI
0.97
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Takeda Science Foundation
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science (15K10358, 15K15426)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
fluoxetine, microRNA expression, miR-663a, neuroblastoma, SK-N-SH cells, SH-SY5Y cells, selective serotonin reuptake inhibitors, neuroprotection, brain development, cell viability, miRNA target genes
MeSH terms
Cell Differentiation, Cell Survival, Fluoxetine, Humans, Neuroblastoma, Up-Regulation, Gene Expression Regulation, Neoplastic, MicroRNAs, Cell Line, Tumor, Neurogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review